Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4281]

FDA approves ribociclib with an aromatase inhibitor and ribociclib and letrozole co-pack for early high-risk breast cancer

FDA approves ribociclib with an aromatase inhibitor and ribociclib and letrozole co-pack for early high-risk...

Inherited changes in BRCA genes linked to increased risk of multiple myeloma

Inherited changes in BRCA genes linked to increased risk of multiple myeloma

Ten-year study shows tomosynthesis improves breast cancer detection

Ten-year study shows tomosynthesis improves breast cancer detection

Quality-of-life outcomes investigated for whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery

Quality-of-life outcomes investigated for whole-breast irradiation vs accelerated partial-breast irradiation after...

Evidence shows that oestrogen blocker treatment does not increase the risk of coronary heart disease in breast cancer patients

Evidence shows that oestrogen blocker treatment does not increase the risk of coronary heart disease in breast...

ESMO 2024: Coaching programme for increased exercise in breast cancer patients

ESMO 2024: Coaching programme for increased exercise in breast cancer patients

ESMO 2024: Immunotherapy improves long-term survival in growing number of cancers

ESMO 2024: Immunotherapy improves long-term survival in growing number of cancers

ESMO 2024: Breastfeeding after breast cancer is safe

ESMO 2024: Breastfeeding after breast cancer is safe

Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer

Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer

ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer

ESMO 2024: Trastuzumab deruxtecan effective against brain mets in HER2-positive breast cancer

More from ecancer